Navigation Links
Neurocrine Biosciences to Present at Credit Suisse's 24th Annual Healthcare Conference
Date:11/4/2015

SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at Credit Suisse's 24th Annual Healthcare Conference in Scottsdale, AZ.

The live presentation takes place on Wednesday, November 11 at 10:30am MT (9:30am PT/12:30pm ET).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.  The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results
2. Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
3. Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
4. Neurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors
5. Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences to Present at the Baird 2015 Healthcare Conference
7. Neurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study
8. Neurocrine Biosciences Reports Second Quarter 2015 Results
9. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2015 Results
10. Neurocrine Biosciences Provides Update on NBI-77860 Program for Congenital Adrenal Hyperplasia
11. Neurocrine Biosciences to Host Analyst and Investor Day in New York City on May 21, 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2020)... (PRWEB) , ... July 02, 2020 , ... Exercise.com, the ... professionals, announced that 913,628,072 lifted pounds were logged through its software during the months ... this new age of fitness – an age where even gym giants like ...
(Date:7/1/2020)... , ... July 01, 2020 , ... Dexur’s analysis of ... University Hospitals Ahuja Medical Center , Southwest General Health Center , and ... episode for Hip & Knee replacement. Dexur’s value analysis tracks a patient’s episode of ...
(Date:6/28/2020)... ... June 28, 2020 , ... Probiotics ... studies substantiate the effectiveness of oral-care probiotics to maximize teeth and gum health. ... science behind both is simple – utilizing naturally occurring positive bacteria to improve ...
Breaking Medicine Technology:
(Date:7/2/2020)... ... July 02, 2020 , ... Allegheny Health Network (AHN) ... Chief Medical Information Officer (CMIO), effective immediately. Dr. Lee succeeds Robert White, MD, ... AHN through the end of the year to help support a seamless transition. , ...
(Date:7/1/2020)... ... ... Dexur’s analysis of Medicare claims of hospitals within a 25-mile radius ... and Sky Ridge Medical Center had the best value outcomes ... patient’s episode of care from the date of admission for 90 days and includes ...
(Date:7/1/2020)... ... 01, 2020 , ... Psilera Bioscience (“Psilera”), a ... announces its core executive team. The co-founders Drs. Jackie Salm and Chris Witowski ... as distinguished researchers within the cannabis industry. They are joined by pharmaceutical and ...
(Date:7/1/2020)... ... July 01, 2020 , ... G-CON Manufacturing, the leader ... Codiak BioSciences to support its cleanroom build out at its new clinical manufacturing ... drug substance and product manufacturing for its clinical pipeline. , Codiak chose PODs ...
(Date:6/28/2020)... ... June 26, 2020 , ... Medisend ... provide high-quality, intensive education and training that prepares graduates for professional careers as ... member of the Board of Trustees. , Ms. Williams currently serves as Associate ...
Breaking Medicine News(10 mins):